GlassScriptPhysician profile
Virginia J Reeder
NPI 1265666820
$22,081.68
in general payments reported to CMS, 2019-2025
40 companies · $3,617 in 2025
The $3,617 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $1,355 · 2021: $2,939 · 2022: $3,711 · 2023: $3,906 · 2024: $4,668 · 2025: $3,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,884.05 |
| Education | $307.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,325.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,052.78 | 2019-2025 | |
| Ucb, INC. | $1,797.41 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,786.41 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $1,641.63 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $1,355.62 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $912.92 | 2019-2025 | |
| Incyte Corporation | $845.07 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $796.49 | 2023-2024 | Vtama |
| Lilly USA, LLC | $751.33 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $678.64 | 2019-2025 | |
| Galderma Laboratories, L.P. | $575.70 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Leo Pharma INC. | $556.03 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $488.78 | 2020-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $348.40 | 2023-2025 | Zoryve |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.